Executive Summary on Global Cannabis Consumer Market Size
Summary
The passage provides generic market estimates and projections for legal and illegal cannabis markets without mentioning any specific individuals, companies, financial transactions, or government actio UNODC estimates global illegal cannabis market at $113 billion in 2003. RAND estimated U.S. illegal cannabis market at $40 billion in 2010, projected $48 billion today. Projection that legal cannabis
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (2)
Tags
Related Documents (6)
Ackrell Capital Cannabis Investment Report compares market size to alcohol, coffee, tobacco, and pharmaceuticals
The document is a commercial investment analysis with no mention of political figures, government agencies, or alleged misconduct. It offers no actionable leads for investigations and contains only pu Provides estimated penetration rates and consumer spending for cannabis versus other legal substance Claims U.S. legal cannabis market size aligns with other retail markets. Published by Ackrell Capi
Ackrell Capital Cannabis Investment Report (Dec 2017) – No substantive investigative leads
The document is a commercial investment report on the cannabis industry with generic market analysis and no mention of specific individuals, transactions, or wrongdoing. It lacks actionable details, n Report outlines cannabis market segments, legal landscape, and forecasts. Contains standard disclosures and acknowledgments from Ackrell Capital, a FINRA/SIPC member. No references to government offi
Cannabis Investment Report – Private Company Funding Totals (2016‑2017 YTD)
The document lists aggregate capital raised by private cannabis‑related firms and a few deal specifics. It contains no references to high‑ranking officials, government agencies, foreign leaders, or al Total capital raised by private cannabis companies grew from $256 M in 2016 to $483 M YTD 2017. Number of deals increased from 65 to 102 in the same period. Largest disclosed private deals in 2017 we
Ackrell Capital Cannabis Company Financial Metrics Table
The document is a plain financial summary of cannabis companies listed on the Canadian Securities Exchange with no mention of influential actors, misconduct, or controversial transactions. It offers n Provides market cap, revenue, EBITDA, and valuation multiples for dozens of cannabis firms. Includes percentages of stock price below enterprise value. No names of political figures, government agenc
Ackrell Capital Cannabis Investment Report – Terpene Benefits Overview (Dec 2017)
The passage is a generic industry report describing terpene profiles and alleged medicinal benefits. It contains no references to high‑profile individuals, government agencies, financial transactions, Describes therapeutic claims for various cannabis terpenes (myrcene, pinene, limonene, camphene). Provides a table of purported medical benefits (antianxiety, anti‑inflammatory, etc.). Published by A
Ackrell Capital Cannabis Investment Report – Terpene Profile (Dec 2017)
The document is a technical cannabis industry report containing terpene percentages and formulation data. It mentions no high‑profile individuals, government agencies, financial transactions, or contr Provides typical terpene composition percentages for cannabis flower. Describes the concept of the “Entourage Effect” and THC:CBD ratio ranges. Published by Ackrell Capital, a FINRA/SIPC‑registered f
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.